Brokerages Set Novavax, Inc. (NASDAQ:NVAX) Target Price at $14.00

Novavax, Inc. (NASDAQ:NVAX) has received an average recommendation of “Hold” from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $14.00.

NVAX has been the topic of a number of recent analyst reports. BTIG Research reaffirmed a “buy” rating and set a $19.00 price target on shares of Novavax in a report on Thursday, June 11th. Weiss Ratings reissued a “sell (d)” rating on shares of Novavax in a report on Tuesday, August 4th. Wall Street Zen raised shares of Novavax from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Zacks Research cut Novavax from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th.

Novavax Stock Performance

Shares of NASDAQ NVAX opened at $9.42 on Thursday. The firm’s 50 day moving average price is $8.62 and its 200-day moving average price is $9.02. The company has a market cap of $1.55 billion, a PE ratio of -6.20 and a beta of 2.45. Novavax has a 52-week low of $6.20 and a 52-week high of $11.97.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.06. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. The company had revenue of $56.70 million during the quarter, compared to the consensus estimate of $52.51 million. During the same quarter last year, the firm earned $0.62 earnings per share. The firm’s quarterly revenue was down 76.2% compared to the same quarter last year. On average, analysts forecast that Novavax will post -0.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Quarry LP purchased a new stake in shares of Novavax during the third quarter worth about $33,000. Duncker Streett & Co. Inc. boosted its position in shares of Novavax by 917.3% during the first quarter. Duncker Streett & Co. Inc. now owns 4,242 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 3,825 shares during the last quarter. KBC Group NV boosted its position in shares of Novavax by 34.9% during the first quarter. KBC Group NV now owns 4,746 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 1,229 shares during the last quarter. Allworth Financial LP grew its stake in Novavax by 292.5% during the second quarter. Allworth Financial LP now owns 4,353 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 3,244 shares in the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new position in Novavax during the second quarter valued at $42,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Key Headlines Impacting Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax outperformed the broader market in the most recent session, according to Zacks. The article highlights the stock’s relative strength, although it does not identify a new fundamental catalyst. Novavax (NVAX) Laps the Stock Market: Here’s Why
• Neutral Sentiment: Novavax presented at Citigroup’s Biopharma Back to School Summit, giving investors an opportunity to assess management’s strategy, pipeline and commercial outlook. No specific new deal, clinical update or financial guidance change was provided in the available summary. Novavax Presents at Citigroup’s Biopharma Back to School Summit 2026
• Neutral Sentiment: Reported short-interest data showed zero shares and a zero-day short-interest ratio for both periods. Because the figures appear anomalous, they do not provide a reliable indication of short-covering pressure or bearish positioning.
• Negative Sentiment: One market commentary piece included Novavax among small-cap stocks viewed skeptically, emphasizing the company’s volatility and risks associated with smaller biotechnology companies. 3 Russell 2000 Stocks We’re Skeptical Of
• Negative Sentiment: Analysts’ average rating on Novavax remains “Hold,” suggesting limited conviction that the stock will deliver substantial near-term gains. Novavax Receives Average Rating of Hold from Analysts

Novavax Company Profile

Novavax, Inc is a biotechnology company focused on discovering, developing and commercializing vaccines for infectious diseases. The company’s vaccine platform uses recombinant nanoparticle technology and Matrix-M, its proprietary saponin-based adjuvant, which is designed to enhance and broaden immune responses.

Novavax’s primary commercial product is Nuvaxovid, a protein-based COVID-19 vaccine authorized in multiple markets. The vaccine has also been marketed as Covovax through partnerships in certain countries.